Interactive Transcript
0:02
Hello, and welcome to Noon Conference hosted by Medality.
0:05
Noon Conference connects the global radiology community through free live
0:09
educational webinars that are accessible for all and is an opportunity to learn
0:12
alongside top radiologists from around the world.
0:16
Today, we're honored to welcome Dr.
0:17
Kevin Chang for a lecture entitled Diffuse Liver Disease. Dr.
0:21
Chang completed his radiology residency at Boston University and his
0:24
cross-sectional imaging fellowship at Johns Hopkins.
0:27
He is section chief of abdominal imaging and director of MRI at Boston University
0:32
Medical Center, associate professor of radiology at Boston University's Chobanian &
0:36
Havisian School of Medicine, and an adjunct associate professor of diagnostic
0:40
imaging at Brown University's Alpert Medical School.
0:43
At the end of the lecture, please join him in the Q&A session where he will address
0:46
questions you may have on today's topic.
0:49
Please remember to use that Q&A feature to submit your questions so we can get to
0:52
as many as we can before our time is up.
0:54
With that, we're ready to begin today's lecture. Dr.
0:57
Chang, please take it from here.
0:59
All right. So great. Thank you for letting me give a talk about one of my favorite
1:05
topics. That's diffuse liver disease.
1:06
I've been talking about this, and I think this topic first came up as a resident
1:12
conference back when I was a resident many, many years ago.
1:15
And the talk has evolved a lot since then.
1:18
There's a lot of topics to cover here, so there will be some topics that I will
1:21
definitely not be able to get much in-depth into, but we will try to get through as
1:26
much as we can and cover as many topics as we can.
1:29
These are my disclosures, none relevant to our topic today.
1:34
So definitely, we're using a lot of cross-sectional imaging for diffuse liver
1:37
disease. There's been a lot of advances in CT and MR technology and techniques.
1:41
A lot of these diagnoses still require biopsy to make a definitive diagnosis, but
1:45
imaging is definitely useful for narrowing differential diagnoses, detecting
1:49
complications of a lot of these disease processes, such as portal hypertension,
1:54
monitoring responses to therapy, as well as following up known diagnoses.
1:59
And increasingly, CT and MR and ultrasound are being used as a metabolic biomarker.
2:04
A lot of these findings are used as a biomarker of disease.
2:07
I'm giving the answers to all these cases right up front here in the form of an
2:12
outline. So these are
2:15
not entirely an all-inclusive list of diseases.
2:20
But we're going to touch on cirrhosis first because that's the hallmark of diffuse
2:25
liver process, as well as all the metabolic and storage-related disease processes.
2:28
These are probably the two most common causes of diffuse liver disease that we
2:32
encounter on a daily basis, multiple times a day.
2:36
There's also other causes of diffuse liver diseases like drug-related responses,
2:42
drug-related imaging findings, as well as some hereditary diagnoses like glycogen
2:47
storage diseases and Wilson's disease, and then some more idiopathic processes like
2:52
amyloidosis. And in addition, there are other causes that can look diffuse as well,
2:58
such as infectious causes, hepatitis, schistosomiasis, and then other causes like
3:05
sarcoidosis, diffuse neoplasm, and then a whole array of vascular
3:10
etiologies that can lead to more diffuse, non-mass-like changes or
3:17
imaging findings on various studies, especially the multi-phase
3:22
contrast enhanced studies. General categories in terms of patterns of disease.
3:27
There are some homogeneous patterns, which are predominantly due to parenchymal
3:33
involvement of hepatocytes in the reticuloendothelial system.
3:38
There are more segmental processes as well that are often related to perfusion
3:43
because these affect certain segments of the liver or subtotal portions of the
3:49
liver. So a lot of this is related to the interesting perfusion pattern of the
3:54
liver due to, it's not only its portal venous and hepatic artery perfusion, but
3:59
also third inflow phenomenon of other collateral vessels that affect certain parts
4:03
of the liver, which we'll get into in a little bit.
4:06
There's nodular, more depositional patterns of disease as well.
4:10
So things that can lead to small little nodules throughout the liver, as well as a
4:14
perivascular distribution related to the lymphatic system and Glisson's capsule.
4:21
So let's start first with the findings that we see multiple times a day.
4:26
That's patients with a liver that's very nodular or lobular in contour.
4:32
Sometimes you'll see other manifestations of this disease process, which is
4:37
cirrhosis, like findings of portal hypertension, such as splenomegaly, which you
4:42
can see here with a big spleen.
4:45
Varices, paraesophageal, perigastric, periesophageal, periesophageal, a bunch of
4:50
portosystemic shunts in various typical locations throughout the abdomen and
4:54
pelvis. Presence of ascites. So these are all findings that we see every day in
4:58
cirrhosis. I'm not going to get too much into detail here because we all see these
5:03
changes and are pretty good at least detecting the findings of moderate to severe
5:08
cirrhosis. This can lead to architectural distortion, and it's these
5:13
macroscopic changes that
5:16
we're the best at detecting. But unfortunately, a lot of these architectural
5:20
distortive changes are more evident with more severe cirrhosis rather than mild
5:24
cirrhosis. Mild cirrhosis we may certainly overlook on imaging alone.
5:30
Different causes. These are the typical causes.
5:32
Alcohol,
5:34
viral causes, as well as other causes like primary biliary cirrhosis and
5:38
hemochromatosis, and metabolic-associated etiologies as well.
5:44
And the reason why we get so worried about this is because of the progression to
5:48
hepatic failure, as well as the manifestations and complications of portal
5:53
hypertension.
5:55
In terms of imaging, like I said before, we're looking for surface nodularity.
5:59
That's probably one of our more specific findings, but a later-stage finding of
6:03
disease.
6:05
Architectural changes usually will manifest as atrophy of certain
6:11
portions of the liver, like the medial left lobe and the portions of the right
6:16
lobe, and enlargement of other portions of the liver, like the caudate lobe and the
6:20
lateral segment of the left lobe. And they can even lead to changes around the
6:25
gallbladder fossa, where you have increased fat around the gallbladder, the
6:29
expanded gallbladder fossa sign.
6:32
Other examples of cirrhosis. We're not going to get too much into the details of
6:36
the complications of cirrhosis, such as hepatocellular carcinoma here.
6:40
That's certainly a huge topic in and of itself, which we're not going to touch on
6:43
here. But here you see masses that have some hemorrhage in them.
6:48
That's typical for
6:51
hemorrhagic hepatocellular carcinoma.
6:53
You've got pseudocapsules, you've got ascites here, got washout, all the typical
6:58
findings for HCC in the setting of cirrhosis.
7:03
Other ways to evaluate cirrhosis.
7:06
We've got elastography now that we do both by MRI as well as ultrasound.
7:11
My institution tends to rely more on MR elastography, where we put an
7:16
acoustic transducer on the abdominal wall, and we send sound waves in, and we can
7:21
visualize the speed of the sound wave propagation through the liver.
7:27
And measuring the speed of the propagation of the sound waves will give you a
7:32
kilopascal measure of liver stiffness.
7:35
And the stiffer the liver, the higher the kilopascal
7:40
number that you can generate from an ROI on the elastography maps.
7:46
Certainly, I'm not an expert in elastography, but we do an increasing number of
7:51
these, trying to stage the severity of fibrosis
7:55
while trying to reduce the number of biopsies that are performed.
8:01
And at the same time, you can do proton density fat fractions as well to judge the
8:04
degree of steatosis. This can be done by ultrasound as well.
8:09
Basically, similar technology, sending a sound wave in, and you're looking at the
8:13
shear wave, the perpendicular shear wave, the velocity of the perpendicular shear
8:17
wave, and correlating that with the relative stiffness of the liver.
8:25
Next topic, beyond cirrhosis, is going to be the other finding that we probably see
8:30
just as much as, if not more commonly than in cirrhosis, and that's when you see
8:36
hepatic steatosis, otherwise known as fatty infiltration of the liver.
8:42
On CT, typically, you'll see diffuse hypodensity of the liver, and this
8:48
can be easier to detect on a non-contrast CT, where contrast enhancement doesn't
8:55
get in the way of evaluating the liver attenuation.
8:59
Typically, you're looking for an attenuation that's less than 40 Hounsfield units
9:03
or something that's more than 10 Hounsfield units,
9:08
less dense than the spleen, which is your internal control.
9:12
On MRI, we'll use T1-weighted imaging because fat is bright on T1, and if we do
9:18
dual echo, gradient echo sequencing, we can look at the in-phase and out-of-phase
9:21
series, the echoes, to determine the degree of signal
9:27
dropout related to Fat and water protons sharing the same voxel.
9:31
So if there's a fat proton and a water proton in the same voxel, on the
9:35
out-of-phase image, the signal intensities are going to cancel each other out, and
9:39
you're going to see a relative drop in signal.
9:41
So in this case, you've got a very T1 bright liver, which diffusely drops out in
9:47
signal on the out-of-phase T1-weighted gradient echo image.
9:52
So there's diffuse homogeneous
9:55
steatosis in the liver. It can be segmental as well.
9:57
So you can see in this case where the out-of-phase images, you're seeing the signal
10:01
drop out in most of the liver, except for the posterior right lobe here.
10:05
And this is related to the segmental anatomy of the liver for one reason or other.
10:09
The posterior right lobe is being relatively spared from the degree of fatty
10:13
infiltration that the rest of the liver is facing.
10:16
So
10:18
focal fatty sparing. Note that these areas that show these signal changes,
10:23
sometimes they can look mass-like.
10:25
But the key here on whatever the imaging modality you're using, whether it's
10:29
ultrasound, CT, or MRI, is that there's no vascular distortion.
10:32
So you'll see the portal triads and the hepatic veins going through these areas
10:36
without any mass effect from these processes.
10:39
And that can be important when you're looking at cases of a more focal fatty
10:43
infiltration or even nodular mass-like areas of fatty infiltration or fatty
10:49
sparing. This is another example that's a little more focal here in the posterior
10:54
right lobe, segment six area of the liver.
10:56
You can see there's an area of decreased attenuation that looks very wedge-shaped,
11:01
non-mass-like, more segmental or geographic in appearance.
11:06
And this is a typical appearance for focal fatty infiltration or focal
11:11
steatotic liver disease. And on MRI, it can be even more evident here.
11:18
Same patient, same case. On the in- and out-of-phase images here, you can see the
11:24
wedge-shaped segmental or subsegmental area of signal dropout on the out-of-phase
11:29
images compared to the in-phase images.
11:31
You can even appreciate that there's higher signal intensity on the in-phase
11:36
because of the summation of the fat and water-related
11:40
signal intensities there, and then they drop out because of the out-of-phase
11:46
sequence, the echo time for the gradient echo sequence.
11:50
Even on T1-weighted images, if you don't use fat saturation, sometimes it'll look a
11:53
little bit brighter because of the fat content, not the water content.
11:57
And if you do a T2 fat saturated sequence, similarly, that signal intensity can
12:01
drop a little bit compared to the non-fat saturated sequence.
12:05
And sometimes you'll see perfusional changes related to this, and that may be one
12:10
of the reasons for why there's focal fatty infiltration.
12:14
Or conversely, if you see the opposite findings, focal fatty sparing may be related
12:19
to differences in the portal vein perfusion pattern for certain portions of the
12:24
liver. And this pattern can also occur in typical areas that
12:30
have what's called a third inflow phenomenon, which we'll get into in a second.
12:35
Here's another case here on CT where you see diffuse hypoattenuation of the liver,
12:41
except for this tiny little wedge-shaped subcapsular area here.
12:45
So there's a little bit of focal sparing in segment, I think this is seven,
12:51
six or seven. And then on the arterial and the venous phase images
12:57
here of this liver mass protocol CT, you can better see that there's an area that's
13:02
responsible for the sparing in terms of a rounded area of
13:08
peripheral nodular discontinuous arterial phase enhancement that fills in
13:13
centripetally on the venous phase.
13:14
So this is a hemangioma at the apex of this area of focal sparing, which explains
13:20
why this whole segment that's subtended by this hemangioma is being relatively
13:26
spared from fatty infiltration. Maybe because there's more hepatic arterial inflow
13:32
and decreased relative portal venous inflow, or there may be some arterial portal
13:37
shunting that's reversing the portal vein perfusion of that segment of the liver.
13:43
So this is one of the causes of what we call FIDs and FADDs, transient hepatic
13:48
intensity differences or transient hepatic attenuation differences in the setting
13:52
of a steatotic liver.
13:57
On ultrasound, oftentimes we'll see diffusely increased echogenicity of the liver,
14:02
which most of the times we end up
14:06
attributing to steatosis. And then what can make that diagnosis even more
14:12
specific, because fat is not the only thing that causes increased echogenicity in
14:16
the liver, just happens to be the most common cause.
14:20
When you see these non-mass-like, more geographic subcapsular or
14:26
pericholecystic or periportal or peri-falciform areas of
14:32
decreased attenuation, these areas are classic locations for focal fatty sparing.
14:37
And when I see that, I'm more confident that the increased echogenicity is probably
14:41
from diffuse liver steatosis. So this is one area here in the deep
14:48
segment four area of the liver, and then this one is a kind of triangular area next
14:53
to the gallbladder, pericholecystic sparing.
14:56
And you can see the liver is definitely much more echogenic than the right kidney,
15:00
which we use as our internal reference for liver echogenicity.
15:05
Same patient on MRI. You can see on the out-of-phase T1 versus the in-phase
15:11
T1 gradient echo images, that same area in the deep
15:18
segment four area of the liver that is showing less dropout than the remainder of
15:23
the liver on the out-of-phase images.
15:26
Similarly, on the T2 weighted images with and without fat saturation, you can see
15:31
that with the fat saturated out, that area is a little bit brighter than the rest
15:36
of the liver parenchyma, which is fatty.
15:38
And then on the pre- and post-contrast multiphase images, you can see there's
15:42
perfusional effects here as well.
15:44
There's a little bit of a hyper enhancement in that area, which is likely
15:48
perfusional rather than mass-like or mass related.
15:53
So steatosis with focal fatty sparing.
15:57
Here's another dramatic example of steatosis with more central sparing in relation,
16:03
or in this case, it was likely secondary to chemotherapy following
16:09
treatment for pancreatic adenocarcinoma.
16:12
So steatotic liver disease can be either from an overproduction or a faulty
16:18
metabolism of fatty acids or decreased hepatic clearance of fatty acids due to
16:22
hepatocellular injury, which could be related to alcohol, could be post-viral
16:27
hepatitis, could be medication related, such as chemotherapy related.
16:33
And the distribution can be pretty variable, can be diffuse, can be focal or
16:37
subtotal, like I showed you in a few cases, with areas of typical sparing or
16:44
focal fatty infiltration. And this can be explained in large part by what
16:50
I think is the third inflow phenomenon.
16:51
It's one of the theories for why certain areas of the liver are either focally
16:56
spared from steatosis or can be focally involved by steatosis.
17:01
Typical areas, like I said, could be related to cystic vein collaterals around the
17:07
gallbladder. So that could explain pericholecystic sparing or pericholecystic focal
17:12
involvement. The veins of Sappey around the falciform ligament
17:18
can explain a lot of the
17:21
areas around the falciform ligament on our various modalities, as well as there are
17:26
other areas of collateral flow as well around the porta hepatis region.
17:33
So third inflow can also explain a lot of our perfusion-related changes in addition
17:38
to areas of fat sparing and fat infiltration.
17:44
All right, so our next case, we're going to move on from steatosis to
17:50
causes of liver hyperattenuation.
17:52
So this is a non-enhanced CT where the attenuation is 75 Hounsfield units.
17:57
Usually, normal range is 45 to 65 Hounsfield units.
18:01
So in this case, this is a hyperdense liver, and there's a broad differential
18:05
diagnosis for a hyperdense liver.
18:07
Could be from amiodarone,
18:10
which is an iodinated deposition.
18:13
Could be from iron, like from hemosiderosis or hemochromatosis.
18:17
Could be from glycogen storage disease, could be from gold therapy, could be from
18:22
copper deposition in Wilson's disease, could be from thoroughgoing.
18:25
So there's a broad category of multiple possible etiologies for
18:31
increased liver density. MRI is a little bit more sensitive in detecting the cause
18:37
of the increased density. In this case, you can see the liver is super dark on a
18:41
T1-weighted image, as well as on
18:44
the gradient echo pre-contrast images, as well as T2-weighted images.
18:48
So in this case, it's the liver as well as the spleen. The spleen is also dark.
18:53
So in this case, when you have
18:57
susceptibility or paramagnetic effects in both the liver and the spleen.
19:01
We're thinking about something that's beyond just hepatocyte deposition.
19:05
We're talking about the reticuloendothelial system.
19:08
So in this case, this is a case of hemosiderosis or iron deposition in both the
19:12
liver and the spleen, and maybe in the bone marrow as well.
19:16
Sometimes you'll see that on an in-and-out-of-phase T1-weighted gradient echo
19:21
image, such as this case here. So you can see not only is the liver and the spleen
19:26
dropping in signal on the in-phase compared to the out-of-phase, because the
19:30
in-phase has a longer echo time than the out-of-phase sequence.
19:33
So in this case, it's the reverse of steatosis.
19:36
Instead of signal dropping on out-of-phase, when you see the signal dropping more
19:40
on the in-phase, that tells you there's something like iron, something that's
19:44
causing a paramagnetic
19:47
susceptibility effect on the liver and the spleen.
19:50
And in this case, the bone marrow as well.
19:52
So typically, since bone marrow tends to have both red and yellow elements, it
19:57
tends to drop more in signal on the out-of-phase than in-phase because of the mixed
20:01
fat and water protons in bone marrow.
20:03
But in this case, the opposite is happening, which tells you that there's iron in
20:08
the reticuloendothelial system of the bone marrow as well.
20:12
So this is another case of more severe hemosiderosis.
20:17
And similarly, on the T2-weighted images, you just see a huge amount of signal
20:22
drop. And this can be even more evident on diffusion-weighted images, where you
20:27
basically see a signal void in the liver on those
20:31
diffusion-weighted images of the various b-values.
20:37
All right. Another case here,
20:40
just to hammer in the point here. We've got out-of-phase and in-phase T1s on the
20:44
top with signal dropout in the liver and the spleen, as well as low signal on
20:48
T2-weighted images, as well as a lack of signal on the diffusion-weighted images
20:53
here. Another case of hemosiderosis.
20:55
Whereas in contradistinction or in contrast, we're seeing another case here
21:01
of T1 gradient echoes here, where there's signal dropout on the in-phase compared
21:05
to the out-of-phase in the liver, but it's sparing the spleen.
21:10
And
21:12
you also see the low signal on the pre and post contrast images here, as well as on
21:17
the diffusion-weighted images. But when you have iron deposition in the liver
21:21
sparing the spleen, we're starting to think about hepatocyte deposition of iron,
21:26
and that's more characteristic for hemochromatosis, primary hemochromatosis, or
21:32
hereditary hemochromatosis.
21:37
This is another case, again, showing low signal in the liver, sparing the spleen.
21:43
Sometimes you'll see the deposition as well in the pancreas, and this is another
21:46
location where hereditary hemochromatosis may show iron deposition
21:52
within cells in the pancreas. Sometimes you also see the same finding in the
21:56
myocardium, if the myocardium is included.
21:58
If the myocardium looks lower signal than usual.
22:01
That's the typical distribution of iron deposition in primary hemochromatosis.
22:06
So again, another case of hemochromatosis.
22:09
This one is another one here showing in and out-of-phase images here.
22:12
Out-of-phase versus in-phase. Signal drop on the in-phase in the liver, sparing the
22:17
spleen. This liver also shows a nodular or lobular contour, so there's secondary
22:23
cirrhosis as a result of the hemochromatosis in this case.
22:27
And the
22:32
next case I'm going to show you here is the same thing with a little bit more of a
22:37
segmental pattern of involvement. The whole liver is dark.
22:40
Maybe there's more signal dropout that's easier to see in the right lobe
22:46
on the in-phase versus the out-of-phase, although the whole liver is dark in
22:49
signal. Except there's a mass in the left lobe here in a patient with
22:52
hemochromatosis that's developed a secondary neoplasm.
22:57
These primary hemochromatosis patients are at elevated risk for developing a
23:01
neoplasm, particularly primary hepatic neoplasms such as a cholangiocarcinoma
23:07
or a hepatocellular carcinoma. And in this particular case, this ended up being an
23:12
intrahepatic cholangiocarcinoma.
23:17
All right. So iron overload.
23:19
Again, to reiterate, primary hemochromatosis is the hereditary autosomal recessive
23:24
disorder of iron metabolism, resulting in excessive deposition in not just the
23:29
hepatocytes of the liver, but the pancreas, the myocardium, and it can also affect
23:33
the joints and the skin. And without treatment, 35% of them can develop a hepatic
23:39
neoplasm. Otherwise, the alternative is the other cause that I showed you.
23:46
First was hemosiderosis or iron overload.
23:48
And this can be either transfusional or it could be related to dyserythropoiesis,
23:54
such as like thalassemia, spherocytic anemia,
23:59
other
24:00
pyruvate kinase deficiencies. So this results in deposition of iron in the
24:04
reticuloendothelial system cells.
24:05
Again, this is going to be the liver, spleen, and bone marrow.
24:09
Usually, it doesn't have the same clinical implications as primary hemochromatosis
24:14
does, unless it's so severe that it's leading to what some people call secondary
24:20
hemochromatosis.
24:24
Here's another case. Again, you can see the T1 gradient echo images out-of-phase
24:28
versus in-phase. There's diffuse signal drop in the liver.
24:31
There's a little bit in the spleen as well.
24:33
But take a look at these adrenal glands. They're super dark.
24:35
So there's a lot of iron being deposited in the adrenal glands in this case.
24:39
And again, on T2-weighted images, you can see similar low signal intensities in the
24:43
liver and the spleen and the adrenal glands.
24:46
And the cause here was due to ferrioxamine deposition.
24:51
So this is more of an iatrogenic cause of iron deposition in multiple organs
24:56
throughout the body. So it's important to note that if somebody's got an anemia
25:00
that they're getting iron therapy for, that if they are going to get an MRI, you'll
25:05
want to try to time the MRI
25:09
to be as far out from the ferrioxamine transfusion as possible, just to reduce
25:13
these artifactual effects of iron deposition, which can be completely
25:19
iatrogenic. In terms of quantifying the iron, so we subjectively looked at iron
25:24
deposition, but we can do quantification by MRI as well.
25:28
And there are two major methods that our institution has used.
25:33
We've basically moved on to the easier-to-perform measure, which is
25:39
generating R2* map and then plugging the ROIs that you get from the R2* relaxation
25:45
times into different formulas that were described by Diego et
25:50
al. in the paper at the bottom there recently.
25:54
So just plugging that number in should give you a liver iron concentration in
25:58
milligrams per gram. And the
26:01
formula differs at 1.5 Tesla versus 3 Tesla.
26:05
There's a vendor-neutral option as well from Yves Gandon, who has some
26:11
free-to-use software online at that address below, where you can plug
26:16
in the relative signal intensities of liver and muscle at various echo times.
26:23
And you can generate the concentrations using the signal decay
26:29
curves from this piece of software as well.
26:31
And this does not require any kind of a vendor-specific pulse sequence to generate
26:37
an R2* relaxation time. I'm not going to get into the details of how it's done, but
26:42
we've got Philips, Siemens, and GE scanners at our institution at various
26:47
field strengths. And basically, these are the slides that I
26:53
use to show the residents and fellows how to measure the ROIs, trying to measure
26:58
areas in the liver with various shapes of ROIs that try to exclude
27:04
major vessels as well as the lung base and
27:07
the adjacent organs. And then basically taking the average of these numbers and
27:12
plugging them into the relative formulas to generate the liver iron concentrations.
27:20
This is Dr. Gandon's piece of software here where you can just plug in different
27:25
ROIs in the liver and the spleen and the muscle and generate these decay curves
27:30
that can separate the relative signal intensity variations related to
27:36
fat infiltration or steatosis, separate from the overall decay curve that's more
27:42
related to the susceptibility effects related to iron.
27:46
And then his pieces of software can even generate the reports for you.
27:51
Good piece of software, but I find the R2* maps to be a lot quicker to measure for
27:57
All right. The next couple topics are going to be a little less
28:03
specific in terms of imaging, so I'm just going to give you a lot of these answers
28:07
right away. But again, we've got another liver here that's hyperdense, measuring
28:11
120 Hounsfield units on the non-contrast phase here, and it's
28:17
affecting the entire liver here. So we can think about that same differential about
28:23
hyperdense liver processes. In this particular patient, it's worth looking at the
28:29
lung bases as well to see if you see any interstitial lung changes.
28:33
Note that this patient also has a cardiac lead, so we know that this patient has
28:37
cardiomegaly and some kind of an arrhythmia.
28:41
In this particular case,
28:43
this patient is on amiodarone therapy, and the iodine in the amiodarone
28:49
can deposit in the liver and give you a hyperdense liver.
28:53
So there's another
28:55
interesting cause of a diffuse liver process that we can see imaging manifestations
29:00
of.
29:02
But in this case, it usually involves looking at the
29:08
medical record to see that they're on amiodarone.
29:14
Okay.
29:16
Next case here, we can see that there's a liver on ultrasound that's more
29:22
echogenic than the kidney. So in most cases, we might think that the patient is
29:27
just another case of a steatotic liver.
29:29
But in this case, if you look at the CT and the MRI, this is not the appearance of
29:34
a fatty liver on CT. No, this liver is hyperdense.
29:39
So what's causing a hyperdense liver on non-contrast CT that's also echogenic on
29:44
ultrasound and very T1 bright on the T1-weighted pulse sequence on MRI?
29:50
So if you compare it to what a normal liver looks like, you can see the liver T1
29:55
signal hyperintensity is even more
30:00
hyperintense than bone marrow, which tends to have some fat in there.
30:04
So this is just another way to gauge the relative T1 signal intensity in liver
30:10
compared to a normal liver. So in this case, this is a glycogen storage disease.
30:15
So this pattern of an echogenic diffuse liver process that's hyperdense on CT and
30:21
T1 bright is a pattern that's probably under-recognized in the setting of glycogen
30:26
storage disease. And patients with glycogen storage disease are predisposed to
30:31
liver neoplasms as well. In this case, this was a
30:35
hepatic adenoma.
30:38
Here's another case of glycogen storage disease, showing you the
30:43
T1 hyperintensity with a focal hyperenhancing mass on the arterial phase here in
30:48
somebody with von Gierke's disease with an adenoma.
30:54
And notice that the adenoma looks like it's dropping in signal a little bit on the
30:59
in-phase versus out-of-phase, but it's actually an optical illusion.
31:04
It's the liver that's dropping a little bit in signal on the out-of-phase compared
31:07
to the in-phase,
31:10
making that adenoma a little bit easier to see in the background of a fatty liver.
31:17
So glycogen storage disease, it's a problem in the use and the storage of glycogen
31:20
due to one of many possible enzyme defects. There's maybe more than 11 now.
31:25
The last time I checked, there was at least 11 known different types of glycogen
31:29
storage disease, and it leads to the deposition of glycogen in the liver.
31:34
And the glycogen deposition in the liver leads to echogenicity in the ultrasound,
31:39
but hyperdensity on CT and hyperintensity on T1-weighted images on MRI.
31:48
Next disease process, which is very nonspecific on imaging, is Wilson's disease.
31:53
This is a rare autosomal recessive disease, often presenting in younger patients.
32:00
The diagnosis is typically more clinical or laboratory-oriented with low serum
32:05
copper and ceruloplasmin levels.
32:08
Copper gets deposited in multiple organs in addition to the liver, such as the
32:13
brain and the cornea. And the liver deposition tends to be periportal and along the
32:18
hepatic sinusoids, invoking an inflammatory reaction.
32:23
Can lead to an acute hepatitis acutely.
32:26
Can lead to steatosis, which can also confound your
32:32
liver attenuation measurements.
32:35
So these patients don't necessarily have a hyperdense liver.
32:37
They can, but not always. And then the more chronic active hepatitis can lead to
32:43
fibrosis and eventual cirrhosis.
32:45
So it's just one of many causes of scarring in the liver, of course, cirrhosis.
32:53
In addition to the variable, sometimes hyperdense appearance on CT can lead to
32:57
hepatomegaly as well. Variable degrees of steatosis and eventual
33:03
cirrhosis. So this is an example from the literature of a very diffuse, kind of a
33:09
multinodular process. Sometimes these
33:14
liver processes can be more diffuse.
33:17
This is a
33:19
patient with multinodular involvement throughout the liver.
33:23
So most of these nodules are
33:26
hypointense. It can be hypointense on T1 and T2.
33:30
This is a patient actually with a different liver process, which is also similarly
33:35
very nonspecific. In this case, this is a patient with amyloidosis.
33:39
Amyloidosis is the deposition of fibrils of protein and mucopolysaccharide
33:45
complexes in multiple different organs.
33:48
The liver is the third most common site behind the spleen and kidney.
33:51
And in the liver, again, these deposition of fibrils are along the hepatic
33:56
sinusoids. The most common appearance is going to be hepatomegaly, and you can get
34:01
these hypodense pseudotumors or little tiny amyloidomas throughout the
34:07
liver, or sometimes you'll see them in the spleen as well as in other organs.
34:11
This is an example of a kind of an area
34:15
of a pseudotumor, or it could even be an area of confluent hepatic fibrosis on a
34:21
T1-weighted image, old image from the literature.
34:24
But here the findings are hepatomegaly,
34:29
you may see ascites, and this pseudotumor area might lead you to believe
34:34
there's amyloid involvement in somebody with a known history of amyloidosis.
34:39
So clinical history is key in interpreting those imaging findings.
34:45
All right. Next disease process here, I'm going to show you an ultrasound through
34:49
the liver. You'll see it looks a little heterogeneous in this case.
34:53
Again, an echogenic liver. Is it fat, or is it something else?
34:58
The liver coarsening, liver hyperechogenicity, liver heterogeneity
35:04
is a very nonspecific finding, which can be related to processes beyond just
35:10
steatosis. In this particular case, you've got some pre- and post-contrast images
35:15
in the liver on MRI, showing you very heterogeneous signal
35:20
intensity and a very heterogeneous enhancement pattern that looks like it's
35:24
following the vasculature in the liver.
35:27
This perivascular appearance is a characteristic finding that we see with liver
35:32
inflammation. In this case, hepatitis, acute hepatitis.
35:36
It can be more segmental as well. In this particular case, on a CT
35:42
scan, you can see there's relative hypoe enhancement involving the medial left lobe
35:47
of the liver with a little bit of capsular retraction, which is a little more
35:51
evident a year later. And this is an area of focal hepatitis that can lead to
35:56
confluent hepatic fibrosis over time.
36:00
On MRI, you can see
36:04
on, again, T1-weighted gradient echo out-of-phase and in-phase images, you can see
36:07
an area of fatty deposition involving predominantly the right lobe of the liver
36:12
with some atrophy of the left lobe here.
36:14
And then on the pre- and post-contrast images on the bottom, you can see a very
36:19
heterogeneous enhancement pattern in the same area along the lateral right lobe of
36:25
the liver in a patient with what looks like hepatitis, in this case,
36:31
possibly related to steatohepatitis.
36:33
So whether the steatohepatitis is metabolic-associated or not, it depends on the
36:41
risk factors of the patient with clinical history.
36:44
So
36:45
hepatitis is basically a nonspecific inflammatory response to hepatic insult.
36:49
Can be from a bunch of different etiologies, infections, autoimmune processes,
36:54
alcohol, drugs, environmental exposures, radiation, metabolic disorders,
37:00
and can be either self-limited, but if it's progressive and chronic, it can lead to
37:04
eventual cirrhosis.
37:08
The scarring and the necrosis inflammation can be focal or diffuse,
37:14
and the acute process can involve the portal tracts, and when it's severe, can lead
37:19
to hepatomegaly and periportal edema.
37:21
But the imaging findings are otherwise relatively non-specific.
37:25
What you're looking for is that heterogeneous enhancement pattern in the acute
37:28
phase can also lead to similar T2 signal intensity differences in a perivascular
37:32
distribution, whereas the late stages will basically resemble early-stage
37:38
cirrhosis. Other findings that can be associated with that would be gallbladder
37:43
wall thickening from edema, ascites, and periportal lymphadenopathy.
37:50
All right. This one's an ANT mini, different disease process.
37:54
You can see what looks like a macrolobular contour to the liver here.
37:58
You can see big, lumpy, bumpy appearance of the liver with areas of hypertrophy.
38:04
But in addition, the
38:07
mini-finding here is calcifications between these segmental, subsegmental areas of
38:12
enlargement, as well as a similar pattern of enhancement along these
38:18
kind of intersegmental areas following contrast administration.
38:23
And then sometimes you'll see similar signal abnormalities on T2 weighted images
38:29
that look like the septations sometimes that you see in the setting of macronodular
38:34
cirrhosis. But the calcifications in this pattern are that giveaway that you're
38:39
dealing with what some people call a kind of a tortoise shell appearance of
38:43
calcifications, something that we typically see with schistosomiasis.
38:48
So schistosomiasis is an infectious cause of a diffuse liver process.
38:53
It's basically
38:58
these adult worms that are water-borne, get into
39:04
the bowel, and then the eggs from these organisms get laid and embolize in the
39:09
mesenteric veins. And these eggs that embolize in the mesenteric veins basically
39:14
shower the liver and end up being deposited in the periportal distribution.
39:19
And one particular schistosomiasis organism is the one that incites this
39:24
calcification kind of a response.
39:26
The schistosomiasis japonicum
39:29
organism. But there's other ones like mansoni and haematobium as well that can
39:34
cause this kind of a
39:38
pattern of involvement. So the periportal
39:43
deposition can lead to the granulomatous reaction and fibrosis and
39:48
calcification in that particular japonicum variant of schistosomiasis.
39:53
So tortoise shell calcifications, schistosomiasis.
39:59
Another very non-specific imaging
40:02
finding of diffuse liver disease is sarcoidosis.
40:05
I'm giving an answer right up front before I show you the images, but it's
40:08
basically a multi-systemic disorder of unknown etiology from non-caseating
40:12
granulomas in almost any organ.
40:16
More often than not, you're not going to see the hepatic involvement from
40:19
sarcoidosis, but sometimes it'll look like tiny little nodular areas of deposition
40:24
in the liver as well as in the spleen.
40:28
More commonly, you'll see the pulmonary manifestations as well.
40:32
So if you see multi-organ involvement, definitely think about sarcoid, particularly
40:38
if the pulmonary findings are more specific in making that diagnosis.
40:43
I think it's easier to recognize this in the lungs than it is in the liver and the
40:48
spleen. But on CT, you'll again may see some heterogeneity in the attenuation
40:54
as well as hepatomegaly and lymphadenopathy.
40:57
You may see some pseudotumors or sarcoidomas in the liver and spleen.
41:03
And similarly, on MRI, you'll see hepatomegaly and
41:08
variable signal intensity. So this is an example of a liver-spleen involvement.
41:12
You can see these tiny little hypodense nodular areas scattered throughout the
41:18
spleen, as well as maybe more subtly in the periphery of the liver here.
41:23
In the same patient in the lungs, you can see your typical kind of a
41:28
periseptal, perifissural, subpleural distribution pattern of
41:34
nodularity and interstitial involvement in a patient with sarcoidosis.
41:38
And then in the same patient on a scrotal ultrasound, you can see a bunch of
41:42
hypoechoic nodules in both testes.
41:46
So this is presumably from diffuse sarcoidosis.
41:53
And this is another patient, again, showing you a bunch of little hypodense nodules
42:00
diffusely scattered throughout the periphery of the liver, maybe some subtle ones
42:03
in the spleen as well. You can see them on ultrasound as well as these little
42:07
hypoechoic areas. And if you saw your typical pattern of pulmonary involvement,
42:13
maybe some lymphadenopathy as well, then you can presume, or you
42:19
can put forth the possibility of sarcoidosis involvement in the liver and the
42:24
spleen.
42:26
This is another case of known sarcoidosis leading to eventual cirrhosis
42:32
in the liver. So you can see the macrolobular pattern of the capsule, as well as
42:38
the expanded gallbladder fossa sign.
42:39
In this particular case, the cirrhosis was from sarcoidosis.
42:45
And then another etiology that can also lead to a very similar pattern of kind of
42:49
multiple small nodules or even a pseudocirrhotic appearance of the liver with
42:54
capsular nodularity and modularity would be diffuse neoplasms as well as treated
43:00
neoplasms. So the typical
43:03
processes that are best known to do this would be metastatic disease, specifically,
43:09
especially from breast cancer, as well as other neoplasms that can affect multiple
43:15
organs like lymphoma and other proliferative processes.
43:19
So
43:21
the poster child of diffuse metastatic involvement is breast cancer, particularly
43:27
after treatment. A lot of these areas of metastatic involvement can tend to atrophy
43:32
and give you this pseudocirrhotic appearance of the liver.
43:38
But there are other diseases that can metastasize and cause a diffuse
43:43
liver disease appearance of the liver, as also does melanoma, islet cell or
43:48
neuroendocrine metastases, pancreatic
43:54
adenocarcinomas, and even colon cancers.
43:59
This is an example. By ultrasound, you can see there's a little bit of coarsening
44:03
of the liver architecture. We know how specific that finding really is. Not very.
44:08
But on CT, multiphase CT, you can see similarly some very subtle hypodense,
44:14
hypoenhancing areas in the left more than right lobe of the liver, as well as
44:20
a kind of a nodular contour to the liver.
44:24
And on PET, you can see there's an FDG avidity in this patient with
44:27
pseudomembranous breast cancer.
44:29
This is another patient with diffuse involvement from breast cancer.
44:34
You can see there are multifocal, ill-defined, hypoenhancing masses in the liver
44:40
pre-treatment. But particularly post-treatment, you can see how a lot of these
44:44
areas atrophy and give you the areas of capsular retraction that can mimic a
44:49
cirrhosis. And you can see the PET here two years later shows no FDG avidity
44:55
following treatment.
44:57
So pseudocirrhosis.
45:02
I'm going to lightly touch on this liver pattern.
45:06
This is an old case where you can see on T2 weighted images, kind of a
45:12
heterogeneous T2 intensities in the periphery of the liver, sparing the central
45:16
liver, whereas on post-contrast, you can see some delayed enhancement centrally
45:19
here.
45:21
You can see filling defects in the portal vein and the IVC in this patient with
45:24
Budd-Chiari syndrome. Here's by CT.
45:30
With the late stages, you can get findings that look just like cirrhosis as well.
45:34
The key being that this heterogeneous enhancement pattern, sometimes you'll get
45:39
that flip-flop enhancement pattern between the peripheral liver and the central
45:43
liver. But if you never quite see the hepatic veins
45:48
and/or the IVC, then start thinking about Budd-Chiari syndrome, particularly if you
45:52
have a phase where you should be seeing the enhancement of the hepatic veins or the
45:57
intrahepatic IVC. So Budd-Chiari syndrome is an obstruction of hepatic venous
46:02
outflow, leading to progressive hepatic failure, can lead to manifestations of
46:08
portal hypertension as well, including ascites.
46:11
In the acute phase, you'll see the heterogeneous enhancement pattern as well as
46:15
areas of portal edema and periportal edema.
46:20
And then in the subacute to chronic phases, you basically see findings of
46:24
intraparenchymal collaterals as well as architectural changes that look like
46:29
cirrhosis. And again, the most specific finding is looking for enhancement
46:35
or lack thereof in the hepatic veins or intrahepatic IVC.
46:40
This is something that we see fairly commonly. This is a CT scan with IV contrast.
46:45
You can see there's a giant heart, particularly the right side of the heart is
46:49
enlarged. You've got right atrial and right ventricular enlargement.
46:52
You've got enlargement of the IVC as well as the hepatic veins.
46:57
So this is contrast reflux from right heart failure.
47:00
So this is another cause of a congestive enhancement pattern in the liver, but in
47:05
this case it's not because of thrombosis in the hepatic veins or IVC, but the
47:12
IVC and the hepatic veins are widely patent and more dilated than usual.
47:16
So this is another cause of a relative decrease in hepatic venous outflow.
47:21
But in this case, it's from the
47:24
failure of the right heart, which the IVC empties into.
47:28
So the enhancement pattern that you can see with this, oftentimes, depending on the
47:33
contrast phase that you are imaging the liver in, is this kind of a
47:39
nutmeg appearance. People call this a nutmeg because if you cut a nutmeg in half,
47:42
it kind of looks like this. So you've got these
47:46
areas of heterogeneity in a perivascular distribution, again, from
47:52
congested hepatic sinusoids. So passive hepatic congestion,
47:57
oftentimes related to right heart failure, but
48:01
leading to this mosaic-like heterogeneous enhancement pattern, oftentimes with
48:07
reflux of the contrast from the right atrium into the IVC and the hepatic veins,
48:10
which remain patent. Sometimes you'll see that perivascular edema pattern as well
48:15
on MRI.
48:19
Okay.
48:20
Next disease entity I'm going to show you here is, this is an MRI, and you can see
48:25
there's T2 weighted images on the left here.
48:28
There's coronal and axial T1 post-contrast images here showing you an interesting
48:33
pattern of
48:35
this fluffy,
48:38
perivascular T2 hyperintensities as well as similar subtle areas of
48:44
enhancement, which follow the blood pool in the liver.
48:48
So these represent little congested or dilated hepatic sinusoids
48:55
filled with blood that's enhancing similar to the hepatic vascular trees.
49:00
So this is not a very specific pattern, but it is a pattern that you should
49:05
recognize for something called peliosis hepatis.
49:09
So these areas are little, tiny, globular areas of vessel-like enhancement.
49:15
They can enhance centripetally or centrifugally.
49:18
They tend to show more continuous enhancement to differentiate them from
49:23
hemangiomas. They don't tend to have much mass effect, and they can be either
49:27
diffuse or focal in the liver, and it's related to sinusoidal dilatation,
49:33
multiple blood-filled Kuner spaces.
49:35
The pathogenesis is a bit uncertain, but oftentimes, the
49:41
Bartonellosis in an immunocompromised patient can explain many of these cases of
49:46
peliosis hepatis. Could also be congenital or medication-related, but at least half
49:51
these cases go unexplained.
49:55
And this diagnosis tends to be associated with patients with chronic wasting.
50:03
Okay. Next disease I'm going to show you here, and we're getting into other
50:09
vascular etiologies for diffuse liver processes and changes in
50:15
imaging appearance. We've got a multiphase CT here.
50:18
This is a dual energy CT, so I'm showing you the iodine map here just to accentuate
50:22
the
50:24
changes in the arterial phase enhancement pattern of the liver.
50:27
So you've got something that looks like a cyst in the right lobe, but around the
50:32
remainder of the right lobe of the liver here, you've got a bunch of areas of
50:36
heterogeneous enhancement
50:39
that disappear on the venous phase.
50:42
So this looks like a transient process in the arterial phase, and the key here is
50:47
noting that the portal vein branches in the right lobe are poorly visualized.
50:53
So in this case, if you can follow the portal vein branches on every venous phase
50:58
CT or MRI that you look at, you'll be able to better explain any perfusion
51:04
changes that are related to that area that's poorly perfused by the portal vein.
51:08
So in this case, this is an example of portal vein branch thrombosis leading to
51:13
arterial phase hyperenhancement from compensatory inflow of the hepatic artery.
51:16
So
51:18
you'd think that a thrombosis would lead to hypo-enhancement, but that doesn't
51:22
happen. That's not the case in the liver.
51:25
It's because the liver has a dual main source of perfusion from
51:30
not just the portal vein, but the hepatic artery as well.
51:33
Oftentimes, when you have portal vein thrombosis, you'll get compensatory earlier
51:39
enhancement from hepatic arterial, recruited hepatic arterial inflow, and that
51:45
tends to be transient and best seen in the arterial phase.
51:48
So this is portal vein thrombosis of the right portal vein branch leading to
51:53
transient hepatic arterial enhancement, which is another
51:59
explanation or another cause of a THAD or a THAD, the intensity difference or the
52:03
attenuation difference that's transient.
52:07
This is another case
52:09
where, again, you can see some more subtle hyperenhancement in that right lobe.
52:14
This patient does have cirrhosis, and there are branches of the portal vein that
52:18
are not well-visualized. Sometimes the branches of the portal vein, subsegmental
52:23
branches of the portal vein, may be difficult to visualize because the caliber
52:29
may narrow over time. Best way to detect it, in
52:35
addition to seeing the transient arterial hyperenhancement of the involved area, is
52:40
to compare with older priors if you have them.
52:44
If you can identify a patent portal vein branch on a prior study that's no longer
52:50
present on the current study, then that's probably the best way to diagnose a
52:54
branch portal vein thrombosis and the THAD or THAD that accompanies it.
52:59
This is a not great quality MR, but showing you the same finding
53:05
on that same patient. These areas of non-enhancement in the branches of the right
53:09
portal vein, as well as the lack of signal voids on the T2 weighted
53:15
images involving those same segments.
53:17
So you can look at multiple pulse sequences to confirm this finding on MRI.
53:25
Okay. And then I think this is my last vascular case.
53:32
Here's an MRI of a patient with a history that I am going to withhold.
53:37
We've got some T1 weighted multiphase images here, pre- and post-contrast.
53:43
This is pre-contrast arterial phase, venous, and then a
53:49
hepatobiliary phase in the setting of Yovist or gadoxate contrast use.
53:56
I'm showing you the T2 weighted image in the upper right, as well as a MIP image
53:59
from that arterial phase here. You can see there's multiple little areas of early
54:05
arterial phase enhancements scattered throughout the liver, as well as maybe you
54:11
can see better on the MIP here in the pancreas.
54:15
Sometimes you'll see it in other organs as well, maybe even in the kidneys and in
54:19
the lungs if you had a chest CT. And on the venous phase, you don't see those areas
54:25
quite as well. These areas of transient hyperenhancement tend to blend in with the
54:30
rest of the liver. And then you see contrast retention on the hepatobiliary phase
54:36
in multiple nodular areas throughout the liver.
54:40
So if you saw this gadoxate retention in the hepatobiliary phase, you'd be
54:45
thinking about focal nodular hyperplasia.
54:49
And focal nodular hyperplasia is one diagnosis, but one of the causes of focal
54:54
nodular hyperplasia, or supposedly the main etiology for focal nodular hyperplasia,
55:00
is arteriovenous malformations underlying the FNHs.
55:06
In this case, this patient had a known history of hereditary hemorrhagic
55:10
telangiectasia, and these are multiple little areas of telangiectasia involving
55:14
multiple organs, including the liver, leading to focal nodular hyperplasia.
55:22
All right. So that was a whirlwind through a bunch of diffuse liver processes, some
55:28
of them more specific than others. We went over cirrhosis briefly.
55:33
We went over metabolic and storage-related etiologies of diffuse liver disease,
55:38
including Steatotic liver disease.
55:41
We didn't get into all the different subcategories of steatotic liver disease.
55:44
That's another whole lecture in and of itself.
55:46
But
55:48
I want to remind you what the current terminology is. That was recently updated.
55:51
It's now known as metabolic associated steatotic liver disease, previously known as
55:56
non-alcoholic fatty liver disease, as well as metabolic dysfunction associated
56:00
steatohepatitis. There's a metabolic associated alcoholic liver disease, as well as
56:06
your old-fashioned alcoholic liver diseases.
56:10
There is causes of iron overload divided into two main categories.
56:15
Hereditary hemochromatosis or primary hemochromatosis, which affects just the
56:20
liver, maybe pancreas, maybe myocardium.
56:23
Versus hemosiderosis, which is reticuloendothelial deposition of iron in the liver,
56:30
spleen, maybe bone marrow. We've got drug-related processes, particularly iodine
56:35
deposition from amiodarone use, chronic amiodarone use.
56:39
Got copper deposition from Wilson's disease, as well as diffuse liver processes
56:44
like amyloidosis and glycogen storage diseases, which are less specific by imaging.
56:52
But good to recognize if you know the clinical history.
56:55
There's infectious causes of various types of hepatitis.
56:58
I showed you one and many appearance of infectious liver process,
57:04
schistosomiasis. And then we went into a little bit of sarcoidosis, as well as
57:09
mimickers of diffuse liver disease, like diffuse neoplastic processes.
57:15
And then we went over the spectrum of vascular findings in the liver that can lead
57:21
to vascular patterns of disease.
57:25
Some of them related to the third inflow phenomenon, leading to areas of focal
57:29
fatty infiltration or focal fatty sparing, as well as other vascular etiologies of
57:35
transient arterial perfusional changes in the liver from a bunch of causes like
57:42
pas de deux hepatic congestion and branch portal vein thrombosis.
57:47
So with that,
57:49
diffuse liver disease is definitely, I find it more challenging than focal liver
57:53
masses. But definitely it's important to recognize these because they
58:00
have important prognostic implications as well as associated risk factors for
58:05
malignancy for some of these processes.
58:08
It's important to increasingly recognize the metabolic syndrome and the
58:13
risks that this
58:16
leads to. And a lot of these also have cardiovascular risks as well.
58:22
So with that, I would be happy to answer any questions you may have.
58:27
Thank you so much for that really in-depth lecture and case review.
58:31
Appreciate that. There are some questions in that Q&A box if you want to pop that
58:35
open.
58:36
Okay.
58:37
It might be at the top of your screen right now.
58:40
So I see four major questions.
58:44
One question is, what is my protocol for measuring hemochromatosis?
58:48
I
58:49
went over our measurement of iron deposition.
58:54
I'm not sure if that's the question you have, but again, right now we're
58:59
using some quantitative MR sequences that differ by vendor, but
59:06
all of them basically will give you an R2* map that you can put an ROI on
59:12
and measure the R2* relaxation time, which we plug into
59:18
that equation that I showed you just to spit out of the iron concentration.
59:22
Or if you don't have access to those quantitative MR sequences, basically you can
59:27
just do a grading echo sequence with eight to 12 different echo times, successively
59:33
longer echo times, to monitor the signal degradation over
59:39
longer echo times, as well as to separate that signal drop effect from
59:45
iron versus the signal drop from the in and out-of-phase effects of fatty
59:51
deposition. And that way, you can actually measure the iron concentration as well
59:55
as the fat fraction. Second question was, how long should you wait after
59:59
ferrioxamine administration before obtaining MRI?
60:03
We don't use a specific cutoff time. I would say the longer the better.
60:07
Maybe at least a couple of months, that these effects can be pretty longstanding,
60:12
but
60:14
we don't have a specific guideline, but that's an excellent question.
60:17
We can certainly look that up online to see what other places are doing.
60:21
We don't encounter it all that often. So we haven't developed a policy around it.
60:28
Another question is about whether we use a T2* sequence for liver iron load.
60:33
You can, and certainly if you can get an R2*, you can get a T2* as well, but the
60:37
formulas that were published are R2* ones, or at least the ones that we're using at
60:42
our institution are related to R2*. But there are ways to do it by T2* as well.
60:47
I would have to look up those formulas.
60:54
And then another question is, why does atrophy only occur in certain segments of
60:58
the liver? Good question. That just seems to be the pattern of disease.
61:01
I'm sure there's an answer to that. I'll have to look that up.
61:05
I'm a pattern recognizer. I'm not great at
61:10
knowing exactly what the etiology for the areas of the relative atrophy are, but
61:15
I'm not sure if it's perfusion related or not.
61:21
And then next question is, does the degree of dropout on in-and-out-of-phase
61:25
imaging correlate to the percentage of steatosis? It can, yes.
61:28
There's certainly some formulas that you can use to try to calculate it, but I
61:33
don't think having just two phases alone or two echo times alone is sufficient to
61:38
really give you a good measure because
61:42
just having two echo times alone doesn't always separate the effects of iron
61:47
deposition from the effects of
61:50
fatty infiltration. So that's the reason why a lot of these sequences
61:56
use way more than two echo times, I think eight to 12 echo times even.
62:01
So while it's feasible and there are some formulas out there, I don't think it's as
62:05
accurate as actually doing the proper proton density fat fraction measurements.
62:11
And then another question is, how do you quantitatively measure hepatic steatosis
62:15
at MR? Good question.
62:17
There was a slide-- I didn't show you that the same quantitative MR sequence that
62:22
we use for iron quantification will also spit out a fat fraction map.
62:27
So we're basically looking at the proton density fat fraction map and just
62:32
generating an ROI over the liver. And it gives you a percentage fat
62:38
fraction for the liver. So that's how we quantify the degree of fat
62:43
by MR. So that's basically what we do.
62:48
I'll usually put in an ROI in the succu fat too, just as a control.
62:52
You know you're looking at the right sequence when you put an ROI over the fat and
62:55
it's close to 100, and then you put it in the liver and you can generate a
62:59
percentage, which you can look up in the tables on that paper that I referenced
63:04
earlier in the talk to quantify or correlate the
63:10
percentage to the relative severity of steatosis.
63:17
And then, yeah, the last question we have here is how would a liver with both
63:21
steatosis and iron deposition behave on in-and-out sequences?
63:24
So that depends on whether there's more fat or more iron, right?
63:27
That's why two echo times alone is not really sufficient to isolate one versus the
63:33
other. And maybe the iron would cause a signal drop on both the in and
63:39
out-of-phase.
63:41
And if there's a lot of fat in addition to the iron, then you may not be able to
63:46
appreciate as much of the iron, the signal drop on the in-phase versus the
63:49
out-of-phase. So it's an excellent question, and the reason why we break out those
63:55
two quantifications into separate
64:00
quantification sequences like the R2* map versus the proton density fat fraction
64:06
map. And I would refer you to the paper I showed you before for more
64:11
details in terms of the physics behind how that works and how they generated the
64:18
values using historical
64:22
biopsy results.
64:25
And I think that's it for our questions.
64:27
I think you got them all. Thank you so much. Thanks so much for being here, Dr.
64:31
Chang, and giving that excellent lecture.
64:32
Oh, thank you. My pleasure.
64:34
Yeah.
64:34
Thank you for the opportunity to share.
64:36
Of course. Yeah. So thank you for everyone else for participating in our new
64:39
conference and asking such great questions.
64:41
Be sure to join us next week on Thursday, October 15th at 12:00 PM Eastern, where
64:45
Dr. Lacey McIntosh will deliver a lecture entitled Atypical Lung Cancers.
64:49
You can register for that at medallia.com and follow us on social media for updates
64:54
on future new conferences. Thanks again for learning with us and have a great day.